Article ID Journal Published Year Pages File Type
6196414 Experimental Eye Research 2016 8 Pages PDF
Abstract

•Repeated dose topical application of trans-resveratrol 0.2% causes:•Sustained intraocular pressure reduction in steroid-induced ocular hypertensive rats.•Increased aqueous humor total MMP-2 level.•Reduced trabecular meshwork (TM) thickness and increased TM cell count.•Restoration of the thickness of ganglion cell layer and inner retina.•Restoration of the retinal redox status.

Steroid-induced hypertension and glaucoma is associated with increased extracellular meshwork (ECM) deposition in trabecular meshwork (TM). Previous studies have shown that single drop application of trans-resveratrol lowers IOP in steroid-induced ocular hypertensive (SIOH) rats. This IOP lowering is attributed to activation of adenosine A1 receptors, which may lead to increased matrix metalloproteinase (MMP)-2 activity. This study evaluated the effect of repeated topical application of trans-resveratrol for 21 days in SIOH animals on IOP, changes in MMP-2 level in aqueous humor, trabecular meshwork and retinal morphology and retinal redox status. We observed that treatment with trans-resveratrol results in significant and sustained IOP reduction in SIOH rats. This IOP reduction is associated with significantly higher aqueous humor total MMP-2 level; significantly reduced TM thickness and increased number of TM cells. Treatment with trans-resveratrol also significantly increased ganglion cell layer (GCL) thickness, the linear cell density in the GCL and inner retina thickness; and significantly reduced retinal oxidative stress compared to the SIOH vehicle-treated group. In conclusion, repeated dose topical application of trans-resveratrol produces sustained IOP lowering effect, which is associated with increased level of aqueous humor MMP-2, normalization of TM and retinal morphology and restoration of retinal redox status.

Related Topics
Life Sciences Immunology and Microbiology Immunology and Microbiology (General)
Authors
, , , , , , , , ,